Robert Lofberg
Overview
Explore the profile of Robert Lofberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Panaccione R, Lofberg R, Rutgeerts P, Sandborn W, Schreiber S, Berg S, et al.
J Crohns Colitis
. 2019 Feb;
13(6):725-734.
PMID: 30753371
Background And Aims: Analyses of Crohn's Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship...
2.
Louis E, Reinisch W, Schwartz D, Lofberg R, Robinson A, Berg S, et al.
Adv Ther
. 2018 Mar;
35(4):563-576.
PMID: 29516410
Introduction: Extraintestinal manifestations (EIMs) in patients with Crohn's disease (CD) are common and associated with additional morbidity. This study aimed to evaluate the effect of adalimumab therapy on EIM resolution...
3.
Westerlind H, Bonfiglio F, Mellander M, Hubenthal M, Brynedal B, Bjork J, et al.
Am J Gastroenterol
. 2016 Aug;
111(8):1211-3.
PMID: 27481432
No abstract available.
4.
Oxelmark L, Lindberg A, Lofberg R, Sternby B, Eriksson A, Almer S, et al.
Eur J Gastroenterol Hepatol
. 2016 Jul;
28(11):1320-8.
PMID: 27472271
Background: There is an increasing interest in complementary and alternative medicine (CAM) in patients with chronic diseases, including those with inflammatory bowel disease (IBD). Patients may turn to CAM when...
5.
Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson A, et al.
J Crohns Colitis
. 2016 May;
10(11):1294-1302.
PMID: 27208386
Background And Aims: Toll-like receptors [TLRs] are potential drug targets for immunomodulation. We determined the safety and efficacy of the TLR-9 agonist DNA-based immunomodulatory sequence 0150 [DIMS0150] in ulcerative colitis...
6.
Cars T, Wettermark B, Lofberg R, Eriksson I, Sundstrom J, Lordal M
J Crohns Colitis
. 2016 Jan;
10(5):556-65.
PMID: 26733406
Background And Aims: Crohn's disease [CD] and ulcerative colitis [UC] are chronic diseases associated with a substantial utilisation of healthcare resources. We aimed to estimate the prevalence of inflammatory bowel...
7.
Mellander M, Ekbom A, Hultcrantz R, Lofberg R, Ost A, Bjork J
Scand J Gastroenterol
. 2015 Dec;
51(5):556-62.
PMID: 26679722
Objective: Microscopic colitis is a common cause of chronic diarrhoea in the Scandinavian countries. This report comprises demographic data, clinical and endoscopic features, and occurrence of coeliac and inflammatory bowel...
8.
Westerlind H, Mellander M, Bresso F, Munch A, Bonfiglio F, Assadi G, et al.
Gut
. 2015 Nov;
66(3):421-428.
PMID: 26525574
Objective: Collagenous colitis (CC) is a major cause of chronic non-bloody diarrhoea, particularly in the elderly female population. The aetiology of CC is unknown, and still poor is the understanding...
9.
Munch A, Bohr J, Miehlke S, Benoni C, Olesen M, Ost A, et al.
Gut
. 2014 Nov;
65(1):47-56.
PMID: 25425655
Objective: This 1-year study aimed to assess low-dose budesonide therapy for maintenance of clinical remission in patients with collagenous colitis. Design: A prospective, randomised, placebo-controlled study beginning with an 8-week...
10.
Kuznetsov N, Zargari A, Gielen A, von Stein O, Musch E, Befrits R, et al.
BMC Gastroenterol
. 2014 Apr;
14:79.
PMID: 24758565
Background: Glucocorticoids (GCS) remain one of the mainstay treatments in the management of ulcerative colitis (UC) but up to a third of patients will ultimately fail to respond and progress...